辰欣药业
(603367)
| 流通市值：61.35亿 | | | 总市值：61.35亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,002,250,189.03 | 2,070,524,393.73 | 1,148,946,834.25 | 4,462,348,636.07 |
| 营业收入 | 3,002,250,189.03 | 2,070,524,393.73 | 1,148,946,834.25 | 4,462,348,636.07 |
| 二、营业总成本 | 2,615,901,369.99 | 1,800,515,626.8 | 954,816,641.05 | 3,866,683,359.6 |
| 营业成本 | 1,285,236,267.21 | 874,863,330.11 | 434,450,480.81 | 1,839,024,242.87 |
| 税金及附加 | 36,479,943.59 | 25,392,380.03 | 14,004,530.11 | 59,379,099.79 |
| 销售费用 | 820,785,390.01 | 599,247,430.73 | 340,416,712.34 | 1,334,659,724.28 |
| 管理费用 | 224,841,086.04 | 139,107,635.89 | 76,351,112.27 | 292,408,155.97 |
| 研发费用 | 272,306,294.13 | 179,089,288.76 | 100,074,377.52 | 374,882,920.16 |
| 财务费用 | -23,747,610.99 | -17,184,438.72 | -10,480,572 | -33,670,783.47 |
| 其中:利息费用 | 5,684,632.21 | 2,688,527.69 | 1,348,244.49 | 6,585,354.54 |
| 其中:利息收入 | 28,654,750.81 | 20,045,163.88 | 12,050,671.27 | 41,586,965.49 |
| 加:公允价值变动收益 | 24,844,374.41 | 8,425,105.66 | -2,075,862.8 | -10,374,508.53 |
| 加:投资收益 | 23,637,115.57 | 18,311,692.4 | 10,844,203.15 | 44,117,533.05 |
| 资产处置收益 | 13,294.63 | 26,289.19 | 2,519,301.44 | 594,288.55 |
| 资产减值损失(新) | -39,585,051.66 | -37,777,561.67 | -30,325,909.56 | -73,496,801.64 |
| 信用减值损失(新) | -5,285,220.61 | -8,393,886.31 | -12,543,531.19 | -2,336,432.75 |
| 其他收益 | 45,839,852.59 | 39,519,346.39 | 19,928,778.05 | 38,408,690.12 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 435,813,183.97 | 290,119,752.59 | 182,477,172.29 | 592,578,045.27 |
| 加:营业外收入 | 3,928,523.8 | 2,679,698.69 | 1,321,616.04 | 6,207,721.77 |
| 减:营业外支出 | 799,249.41 | 736,054.83 | 104,001.51 | 2,928,934.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 438,942,458.36 | 292,063,396.45 | 183,694,786.82 | 595,856,832.21 |
| 减:所得税费用 | 35,590,147.65 | 18,346,934.41 | 21,513,432.4 | 70,430,488.46 |
| 六、净利润 | 403,352,310.71 | 273,716,462.04 | 162,181,354.42 | 525,426,343.75 |
| 持续经营净利润 | 403,352,310.71 | 273,716,462.04 | 162,181,354.42 | 525,426,343.75 |
| 归属于母公司股东的净利润 | 398,119,097.94 | 270,316,954.65 | 162,863,217.96 | 521,338,330.89 |
| 少数股东损益 | 5,233,212.77 | 3,399,507.39 | -681,863.54 | 4,088,012.86 |
| (一)基本每股收益 | 0.88 | 0.6 | 0.36 | 1.15 |
| (二)稀释每股收益 | 0.88 | 0.6 | 0.36 | 1.15 |
| 八、其他综合收益 | -656,483.48 | 451,365.02 | 1,764,577.67 | 244,782.98 |
| 归属于母公司股东的其他综合收益 | -656,483.48 | 451,365.02 | 1,764,577.67 | 244,782.98 |
| 九、综合收益总额 | 402,695,827.23 | 274,167,827.06 | 163,945,932.09 | 525,671,126.73 |
| 归属于母公司股东的综合收益总额 | 397,462,614.46 | 270,768,319.67 | 164,627,795.63 | 521,583,113.87 |
| 归属于少数股东的综合收益总额 | 5,233,212.77 | 3,399,507.39 | -681,863.54 | 4,088,012.86 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-23 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |